Targeting mTOR: A Little Bit of History and a Large Future

Jan 31, 2017 by in ONCOLOGY Comments Off on Targeting mTOR: A Little Bit of History and a Large Future

Fig. 1.1 Chemical structure of rapamycin and rapalogs. Rapalogs have the indicated O-substitutions at the C-40 position of rapamycin (red circle) Temsirolimus, formerly known as CCI-779; Torcel®, Wyeth Pharmaceuticals, now…

read more

The Role of mTOR Inhibitors in Breast Cancer

Jan 31, 2017 by in ONCOLOGY Comments Off on The Role of mTOR Inhibitors in Breast Cancer

  Patient population N Design Treatment arms Stratification factors Endpoints Results BOLERO-1 HER2+ ABC. First line 719 Randomization 2:1 Everolimus or placebo 10 mg/day + paclitaxel 80 mg/m2 days 1, 8, 15 + trastuzumab…

read more
Get Clinical Tree app for offline access